Page 82 - FBL AR 2019-20

Fermenta Biotech Limited
Annual Report 2019-20

Details of remuneration of Directors for the financial year ended March 31, 2020 are as follows:
Name of Director Sitting Fees* Salary (H) Contribution Benefits & Total (H) No. of shares
(H) to PF and other Perquisites held (FV of H5)
funds (H) (H)
Mr. Sanjay Buch 9,00,000 - - - 9,00,000 NIL
Independent Director
Ms. Rajeshwari Datla 5,30,000 - - - 5,30,000 5,09,718
Non-Executive Director
Mr. Vinayak Hajare 6,40,000 - - - 6,40,000 NIL
Independent Director
Mr. Krishna Datla** 2,60,000 1,44,75,000 19,66,500 1,35,62,791 3,02,64,291 24,19,074
Managing Director +
Mr. Satish Varma*** 2,50,000 1,12,50,000 15,12,692 87,95,596 2,18,08,288 23,160
Non-Executive Director (up
to September 26, 2019)
Executive Director (w.e.f.
September 27, 2019) +
Dr. Gopakumar Nair 7,50,000 - - - 7,50,000 6,000
Non-Executive Director
(w.e.f. May 17, 2019)
Ms. Anupama Datla Desai*** - 78,70,000 46,05,503 11,09,308 1,35,84,811 4,05,492
Executive Director (w.e.f.
September 27, 2019) +
TOTAL 33,30,000 3,35,95,000 80,84,695 2,34,67,695 6,84,77,390 33,63,444
* Sitting Fees include fees for –
Board and Committee Meetings at H40,000 and H10,000 per meeting respectively (up to November 13, 2019); and
Board, Audit Committee and other Committee Meetings @ H1,00,000; H50,000 and H10,000 per meeting respectively (w.e.f. November 14, 2019).
* Sitting fees include fees paid to non-executive directors of the Company and of erstwhile Fermenta Biotech Limited (Transferor Company).
** The agreement between the Company and the Managing Director is for a period of three years effective May 9, 2018 with a loss of office clause. Either party is
entitled to terminate the said agreement by giving not less than three months’ notice in writing to the other party or such other period as may be mutually decided.
*** The agreement between the Company and the Executive Directors is for a period of three years effective September 27, 2019 with a loss of office clause and is
subject to member’s approval in this AGM. Either party is entitled to terminate the said agreement by giving not less than three months’ notice in writing to the
other party or such other period as may be mutually decided.
+ The remuneration details including the commission payable to the Managing Director and Executive Directors for FY 2019-20 are provided in the Extract of the
annual return for FY 2019-20 and is available on the Company’s website at https://fermentabiotech.com/annual-returns.php
The Company has not granted any Stock Option to any Director. There has been no materially relevant pecuniary transaction or relationship
between the Company and its Non-Executive / Independent Directors during the year under review, except as stated above.
The Non-Executive Directors receive sitting fees for attending the meetings of Board of Directors and its Committees.
STAKEHOLDERS RELATIONSHIP COMMITTEE

• During the year under review, four Stakeholders Relationship Committee meetings were held on May 24, 2019, August 05, 2019,
November 13, 2019 and February 12, 2020. The composition of the Committee as on March 31, 2020 and the attendance at the said
Committee meeting is as follows:
Name of the Director Designation Meetings attended
Mr. Sanjay Buch Chairman 4
Mr. Vinayak Hajare Member 4*
Mr. Krishna Datla Member 4
Mr. Satish Varma Member 4
* Attended one meeting via teleconferencing.
The Company Secretary acts as a Secretary to Stakeholders Relationship Committee.

80